Signal detection of adverse reactions for bendamustine based on FDA adverse event reporting system

CONCLUSION: Our findings identified numerous common AEs with previously reported clinical observations. We also identified some signs of potential new AEs, indicating the need of careful clinical monitoring of patients treated with bendamustine and further risk identification research about this drug.PMID:38682580 | DOI:10.1080/14740338.2024.2348573
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Source Type: research